Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation

Therapeutic resistance is a fundamental obstacle in cancer treatment. Tumors that initially respond to treatment may have a preexisting resistant subclone or acquire resistance during treatment, making relapse theoretically inevitable. Here, we investigate treatment strategies that may delay relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Deepti, Taylor, Bradford P., Chatila, Walid K., Scher, Howard I., Schultz, Nikolaus, Razavi, Pedram, Xavier, Joao B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Targeting Drug Resistance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081172/
https://www.ncbi.nlm.nih.gov/pubmed/35247928
http://dx.doi.org/10.1158/1535-7163.MCT-21-0574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081172/
https://www.ncbi.nlm.nih.gov/pubmed/35247928
http://dx.doi.org/10.1158/1535-7163.MCT-21-0574

Ejemplares similares